Calgary’s Syantra announced today that its blood test for the detection of breast cancer can now be marketed in Europe.
Securing CE marking allows the company to market the blood test in the European Union and other countries that recognize the designation.
Syantra is a precision healthcare startup that’s changing the way cancer detection and treatment are undertaken.
Its flagship product, the Syantra DX Breast Cancer test, is a screening blood test for the detection of breast cancer that utilizes a suite of biomarkers and proprietary artificial intelligence-generated algorithms to provide a positive or negative result.
Calgary.tech named Syantra was one of 10 homegrown Calgary startups to watch in 2023 earlier this year.
CE marking indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health and environmental protection requirements. It is required for products manufactured anywhere in the world that are then marketed in the EU.
“Obtaining CE marking for the Syantra DX Breast Cancer test brings us one step closer to helping women across the globe detect breast cancer at earlier stages when it is most treatable,” said Dr. Kristina Rinker, Syantra Co-founder and Chief Scientific Officer.
In 2022 Syantra raised a $6.8 million Series A fundraising round that was led by a consortium group of doctors in Canada through Rejuvenation Health and included Plug and Play Alberta. Previous investors include Thin Air Labs and The51 Ventures.